Most Recent GBI Research Market Studies on Pharmaceuticals

19 Jan 2012 • by Natalie Aster

Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014. Global Musculoskeletal Disorders Therapeutics Market to Witnesses Moderate Growth as Generic Share Continues to Rise Global Musculoskeletal Disorders market was approximately valued $33.4 billion, representing a compound annual growth rate (CAGR) of 5.7% between 2002 and 2010. By 2017, the global market is estimated to reach $54.8 billion, indicating a CAGR of 7.3% between 2010 and 2017.

Global Musculoskeletal Disorders Therapeutics Market to Witnesses Moderate Growth as Generic Share Continues to Rise Global Musculoskeletal Disorders market was approximately valued $33.4 billion, representing a compound annual growth rate (CAGR) of 5.7% between 2002 and 2010. By 2017, the global market is estimated to reach $54.8 billion, indicating a CAGR of 7.3% between 2010 and 2017.

The market is expected to witness a series of patent expiries between 2010 and 2017, which includes some top selling drugs such as Cymbalta (duloxetine HCl) and Celebrex (celecoxib). While the current market pipeline has a prospect for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Muscular dystrophy is one of the most commonly recognized musculoskeletal disorders, but there are no approved therapeutic options available for this disease. For this reason, the market’s generic share continues to rise.

Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth. Global Antifungals Market will grow at a moderate rate due to the impact of generic erosion in the dermatophytosis and candidiasis markets. There is no dominant player in the market, which is highly fragmented. Although it was worth $9.4 billion in 2010, the majority of revenues came from generic products and not from the branded products.

A high diagnosis rate is a driver for market growth. Current diagnostic techniques involve self diagnosis, fungal culture, microscopy and Enzyme-Linked Immunosorbent Assay (ELISA) tests, for which sensitivity and accuracy is not very high. Advances in the form of beta glucan tests and aspergillus GM EIA (Galactomannan Enzyme Immunoassay) as well as increased patient awareness will increase diagnosis rates, further supporting market growth. Untapped market can only be accessed if the treatment seeking and diagnosis rates improve.

Price per Report: $3,500 (Single User License)

More new market research reports by can be found at GBI Research page. 

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com